Eli Lilly and Company (NYSE:LLY) Shares Acquired by Connors Investor Services Inc.

Connors Investor Services Inc. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,430 shares of the company's stock after purchasing an additional 1,709 shares during the period. Eli Lilly and Company comprises approximately 1.6% of Connors Investor Services Inc.'s holdings, making the stock its 22nd largest holding. Connors Investor Services Inc.'s holdings in Eli Lilly and Company were worth $16,544,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock valued at $57,320,226,000 after purchasing an additional 475,530 shares during the period. Geode Capital Management LLC raised its holdings in Eli Lilly and Company by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock worth $13,389,651,000 after acquiring an additional 291,875 shares during the last quarter. Wellington Management Group LLP lifted its position in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after acquiring an additional 2,012,129 shares in the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $8,407,908,000. Finally, Capital Research Global Investors increased its holdings in Eli Lilly and Company by 16.1% in the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after buying an additional 1,493,673 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,002.80.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $31.00 during midday trading on Friday, reaching $825.10. 6,056,616 shares of the stock traded hands, compared to its average volume of 3,482,066. The company's 50 day moving average is $826.90 and its 200 day moving average is $816.98. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a market capitalization of $782.34 billion, a PE ratio of 70.46, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period last year, the firm earned $2.58 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.